Respiratory syncytial virus (RSV) is a major cause of severe lower respiratory tract infections
and hospitalization in infants under 1 year of age and there is currently no market-approved …

HIV infection can be effectively treated by lifelong administration of combination antiretroviral
therapy, but an effective vaccine will likely be required to end the HIV epidemic. Although the …

ABSTRACT The ALVAC-HIV/AIDSVAX-B/E RV144 vaccine trial showed an estimated
efficacy of 31%. RV144 secondary immune correlate analysis demonstrated that the …

The Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is required for
suppressing viraemia, through mechanisms which remain poorly understood. Here, we …

The immunostimulants 3-O-desacyl-4'-monophosphoryl lipid A (MPL) and the saponin QS-
21 are part of licensed or candidate vaccines. MPL and QS-21 directly affect the innate …

Background. The long-term impact of allogeneic hematopoietic stem cell transplantation
(HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving …

Untreated HIV-1 infection typically progresses to AIDS within 10 years, but less than 1% of
infected individuals remain healthy and have normal CD4+ T cell counts and undetectable …

Induction of antibodies that neutralize a broad range of human immunodeficiency virus type
1 (HIV-1) isolates is a major goal of vaccine development. To study natural examples of …

Non-neutralizing antibodies (nnAbs) to HIV-1 show little measurable activity in prevention or
therapy in animal models yet were the only correlate of protection in the RV144 vaccine trial …

We have developed a high‐throughput platform to detect the presence of HIV‐1 and SIV‐
specific ADCC‐mediating antibody responses. The assay is based on the hydrolysis of a cell …